“Wound Debridement Market is expected to Reach $1.92 Billion By 2029”, says Visiongain report

08 January 2020
Pharma

Visiongain’s new report the Wound Debridement Market Report 2019-2029: Forecasts by Product (Gels, Ointments & Creams, Surgical Devices, Medical Gauzes, Mechanical Debridement Pads, Ultrasonic Devices, Others), by Wound Type (Venous Leg Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Surgical & Traumatic Wounds, Burns, Others), by Method (Autolytic Methods, Enzymatic Methods, Surgical Methods, Mechanical Methods, Others), by End User (Hospitals, Clinics, Others), plus analysis of leading companies operating in the global wound debridement market.

Increasing prevalence of diabetes and associated wounds, rising aging population in developed as well as developing economies, increasing incidences if burn injuries and increasing awareness regarding wound care management are expected to spur global wound debridement market over the forecast period. In 2019, the global wound debridement market was valued at $830 million and is expected to reach $1.92 billion by 2029 at a healthy growth rate of 8.7%.

Growing incidences of diabetes, pressure ulcers, and other chronic diseases are encouraged wound care management providers over the past few years and the trend is expected to continue over the coming years. According to the World Health Organization, in 1980, the number of people diagnosed with diabetes was nearly 108 million and this figure has increased to more than 450 million in 2018. Additionally, a hectic lifestyle, increasing working hours, and an unhealthy diet has resulted in increased prevalence of diabetes in the young population. For instance, according to the World Health Organization, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to more than 9% in 2018.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever